Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8263600 | SCHERING | Antifungal composition with enhanced bioavailability |
Apr, 2022
(1 year, 1 day ago) |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 15 September, 2006
Treatment: NA
Dosage: SUSPENSION;ORAL
4
United States
2
Japan
2
Australia
2
European Union
1
Argentina
1
Brazil
1
Hungary
1
South Africa
1
New Zealand
1
Canada
1
Mexico
1
Peru
1
Norway
1
Poland
1
Korea, Republic of
1
Taiwan, Province of China
1
China
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6790837 | SCHERING | Ribavirin syrup formulations |
Apr, 2023
(2 days from now) | |
US6790837
(Pediatric) | SCHERING | Ribavirin syrup formulations |
Oct, 2023
(6 months from now) |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 29 July, 2003
Treatment: NA
Dosage: SOLUTION;ORAL
3
United States
1
South Africa
1
Denmark
1
Austria
1
Mexico
1
Australia
1
Hong Kong
1
Slovenia
1
Hungary
1
Norway
1
Germany
1
Argentina
1
Colombia
1
Brazil
1
Portugal
1
Cyprus
1
Spain
1
Korea, Republic of
1
Peru
1
Poland
1
Taiwan, Province of China
1
China
1
Japan
1
Canada
1
New Zealand
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic